



Sangamo BioSciences, Inc.
Point Richmond Tech Center
501 Canal Blvd., Suite A100
Richmond, CA 94804
510-970-6000 • 510-236-8951(Fax)

Sangamo BioSciences Announces Four Scientific Publications by Company Scientists

Richmond, California – March 19, 2002 – Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced publication of research articles and reviews in four scientific journals.

“Sangamo has assembled an outstanding team of scientists who are focused on the development and application of our zinc finger DNA binding protein transcription factor (ZFP-TF) gene regulation technology platform,” said Edward Lanphier, Sangamo’s chief executive officer and president. “As our science continues to progress we will publish and present new data in high-impact, peer-reviewed journals and at major scientific meetings, broadening the appreciation for the breadth and differential advantages of our technology.”

The following articles authored by Sangamo scientists were recently published:

Validated Zinc Finger Protein Designs for All 16 GNN DNA Triplet Targets. *The Journal of Biological Chemistry* 277: 3850-3856. Liu, Q., Xia, ZQ., Zhong, X. and Case, C. C.

Biotechnologies and Therapeutics: Chromatin as a Target. *Current Opinion in Genetics and Development* 12: 233-242. Reik, A., Gregory, P. D. and Urnov, F. D.

Methods for the Analysis of Protein-Chromatin Interactions. *Molecular Biotechnology* 20: 1-15. Brickwood, S. J., Myers, F. A. and Chandler, S. P.

Plant Chromatin: Development and Gene Control. *Bioessays* 24: 234-243. Li, G., Hall, T.C. and Holmes-Davis, R.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel transcription factors for the regulation of gene expression. The company’s most advanced therapeutic development program involves the use of transcription factors for the treatment of cardiovascular disease. Additional therapeutics development programs are focused on cancer and other diseases. Sangamo’s core competencies enable the engineering of transcription factors known as zinc finger DNA-binding proteins, or ZFPs. By engineering ZFPs so that they can recognize a specific gene, Sangamo has created ZFP transcription factors that can control gene expression and, consequently, cell function. The company intends to establish ZFP TFs as a widely used technology for commercial applications in human therapeutics, pharmaceutical discovery, agriculture and industrial biotechnology. Over twenty leading pharmaceutical and biotechnology companies have utilized ZFP TFs. For more information about Sangamo, visit the company’s web site at <http://www.sangamo.com/>

This press release may contain forward-looking statements based on Sangamo’s current expectations. These forward-looking statements include, without limitation, references to the research, development and potential applications of ZFP TFs and Sangamo’s ZFP TF technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, our ability to develop commercially viable products and technological developments by our competitors. See the company’s SEC filings, and in particular, the risk factors described in the company’s Annual Report on Form 10-K and its most recent 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.

Contact: Edward Lanphier
510-970-6000, x207

###